Fibroblast Growth Factor Receptor Activating Gene 1 (FRAG1), Related Proteins and Methods
Description of Invention:
These applications describe the identification, isolation and cloning of the human gene named Fibroblast Growth Factor Receptor Activating Gene I (FRAG1) as well as its rat homolog. A full length clone of the human FRAG1 was deposited and the partial sequence (about 90%) is disclosed. The complete sequence of the rat homolog is disclosed.
The gene for FRAG1 encodes a protein which activates the known growth factor receptor, Fibroblast Growth Factor Receptor 2 (FGFR2). FRAG1, when fused to FGFR2, leads to a transformed phenotype when transfected into cells and enhanced levels of phosphorylation/activation of FGFR2. The FGFR2-FRAG1 fusion protein was isolated from an osteosarcoma. Products derived from the FRAG1 cDNA, protein or antibodies which recognize the FRAG1 antigen are likely to be useful as diagnostics, therapeutics and research reagents.
This work has appeared, in part, in Lorenzi, MV, et al. "FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement" PNAS, USA 93(17): 8956-61 (Aug. 20, 1996).
Inventors:
MV Lorenzi (NCI) T Miki (NCI)
Patent Status:
DHHS Reference No. E-124-1996/0 --
U.S. Patent 6,323,316 issued 27 Nov 2001
U.S. Patent 6,608,181 issued 19 Aug 2003
U.S. Patent 6,831,170 issued 14 Dec 2004
U.S. Patent Application No. 10/993,191 filed 18 Nov 2004
Portfolios: Cancer
Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Cancer -Therapeutics
For Additional Information Please Contact: Susan S. Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4478
Email: ruckersu@mail.nih.gov
Fax: (301) 402-0220
